Association of age at menarche, parity, and hormonal contraceptive use with the histologic type of ovarian cancer
Downloads
HIGHLIGHT
1. Relationship between age at menarche, parity, and contraceptive use with histologic type of ovarian cancer was analyzed.
2. A number of patients with ovarian cancer were analytically observed with retrospective cross-sectional approach and the histologic types of the cancer were determined.
3. Age of menarche, parity, and hormonal contraceptive use was found not to have significant correlation with histologic type of ovarian cancer.
ABSTRACT
Objectives: This study analyzed the relationship between age at menarche, parity, and contraceptive use with histologic type of ovarian cancer.
Materials and Methods: This study used an observational analytic with a retrospective cross-sectional approach. The research samples were 128 patients with ovarian cancer at Dr. Saiful Anwar Hospital, Malang, Indonesia, in 2017-2019. All patients underwent primary staging laparotomy. The histologic types of the ovarian cancer consisted of serous type as many as 45, mucinous 45, endometrioid 10, clear cell 20, and others 4. Data analysis used chi-square test.
Results: The p value for the relationship between age of menarche and histologic type of ovarian cancer was p=0.500 (p> 0.05), parity p=0.313, and contraceptive use p=0.824. The distribution of clear cell was more common in multiparous, 40% of endometrioid found in nulliparous, while serous were more common in women with hormonal contraceptive use >5 years, whereas mucinous were more common in those with history of use of <5 years.
Conclusion: There was no significant relationship between age of menarche, parity, and hormonal contraceptive use on histologic type of ovarian cancer.
Yang H, Dai H, Li L, et al. Age at menarche and epithelial ovarian cancer risk: A meta-analysis and Mendelian randomization study. Cancer Med. 2019;8(8):4012-4022. doi: 10.1002/cam4.2315. Epub 2019 May 30. PMID: 31145551; PMCID: PMC6639189.
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12. Erratum in: CA Cancer J Clin. 2020;70(4):313. PMID: 30207593.
Meinhold-Heerlein I, Hauptmann S. The heterogeneity of ovarian cancer. Arch Gynecol Obstet. 2014;289(2):237-9. doi: 10.1007/s00404-013-3114-3. PMID: 24318356.
Matz M, Coleman MP, Sant M, et al. The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2). Gynecol Oncol. 2017;144(2):405-413. doi: 10.1016/j.ygyno.2016.10.019. Epub 2016 Dec 6. Erratum in: Gynecol Oncol. 2017 Dec; 147(3):726. PMID: 27931752; PMCID: PMC 6195192.
Kurman RJ, Shih IeM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. Hum Pathol. 2011;42(7): 918-31. doi: 10.1016/j.humpath.2011.03.003. PMID: 21683865; PMCID: PMC3 148026.
Terada KY, Ahn HJ, Kessel B. Differences in risk for type 1 and type 2 ovarian cancer in a large cancer screening trial. J Gynecol Oncol. 2016;27(3) :e25. doi: 10.3802/jgo.2016.27.e25. PMID: 2702 9746; PMCID: PMC4823356.
Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017;14(1):9-32. doi: 10.20892/j.issn.2095-3941. 2016.0084. PMID: 28443200; PMCID: PMC 5365187.
Cook L, Pestak C, Leung A et al. Combined oral contraceptive use before the first birth and epithelial ovarian cancer risk. Br J Cancer 2017;116:265–9. doi: 10.1038/bjc.2016.400.
Wentzensen N, Poole EM, Trabert B, et al. Ovarian cancer risk factors by histologic subtype: An analysis from the ovarian cancer cohort consortium. J Clin Oncol. 2016;34(24):2888-98. doi: 10.1200/JCO.2016.66.8178. Epub 2016 Jun 20. PMID: 27325851; PMCID: PMC5012665.
Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. Int J Womens Health. 2019;11:287-299. doi: 10.2147/IJWH. S197604. PMID: 31118829; PMCID: PMC 6500433.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5-29. doi: 10.3322/caac.21254. Epub 2015 Jan 5. PMID: 25559415.
Gaitskell K, Green J, Pirie K, et al. Million Women Study Collaborators. Histological subtypes of ovarian cancer associated with parity and breastfeeding in the prospective Million Women Study. Int J Cancer. 2018;142(2):281-289. doi: 10.1002/ijc.31063. Epub 2017 Oct 12. PMID: 28929490; PMCID: PMC5725697.
Fathalla MF. Incessant ovulation and ovarian cancer - a hypothesis re-visited. Facts Views Vis Obgyn. 2013;5(4):292-7. PMID: 24753957; PMCID: PMC3987381.
Trabert B, Tworoger SS, O'Brien KM, et al. The risk of ovarian cancer increases with an increase in the lifetime number of ovulatory cycles: an analysis from the ovarian cancer cohort consortium (OC3). Cancer Res. 2020;80(5):1210-1218. doi: 10.1158/ 0008-5472.CAN-19-2850. Epub 2020 Jan 13. PMID: 31932455; PMCID: PMC7056529.
Yang HP, Murphy KR, Pfeiffer RM, et al. Lifetime number of ovulatory cycles and risks of ovarian and endometrial cancer among postmenopausal women. Am J Epidemiol. 2016;183(9):800-14. doi: 10. 1093/aje/kwv308. Epub 2016 Apr 15. PMID: 27190045; PMCID: PMC4851993.
1. Copyright of the article is transferred to the journal, by the knowledge of the author, whilst the moral right of the publication belongs to the author.
2. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution-Non Commercial-Share alike (CC BY-NC-SA), (https://creativecommons.org/licenses/by-nc-sa/4.0/)
3. The articles published in the journal are open access and can be used for non-commercial purposes. Other than the aims mentioned above, the editorial board is not responsible for copyright violation
The manuscript authentic and copyright statement submission can be downloaded ON THIS FORM.
